BVC
BVC, licence 80143054: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Designs for Health Ltd.
- NPN or DIN-HM
- 80143054
- Status
- Active licence
- Licence date
- 30 July 2025
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Phosphatidylsérine Source : Helianthus annuus - Graine | 50.0 mg | Not calculated |
| Sel interne de (2R)-2-(Acétyloxy)-3-carboxy-N,N,N-triméthyl-1-propanaminium Source : Dichlorhydrate d'arginate d'acétyle-L-carnitine | 212.0 mg | Not calculated |
| Cytidine-5'-pyrophosphate de choline(ester) Source : Citicoline sodium | 125.0 mg | Not calculated |
| L-alpha-Glycérophosphorylcholine Source : Alfoscérate de choline | 100.0 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Extract : Matériel brut sec Extraction ratio : 50:1 Dry plant equivalent : 2500 mg Potency : 5.4 % Terpene lactones | 50.0 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Potency : 24.0 % Flavonoid glycosides | Not specified | Not calculated |
| Coffea arabica Source : Coffea arabica - Fruit Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 1000 mg Potency : 40.0 % Chlorogenic acids | 50.0 mg | Not calculated |
Non-medicinal ingredients
Phosphate dicalcique, Silice, Stéarate de magnésium, Hypromellose, Phosphate de tricalcium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 Année(s) | 2.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps (to) enhance cognitive function and/or memory in adults. Helps (to) improve sustained attention.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80143054
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.